Domača stranPRENW • NASDAQ
add
Prenetics
0,014 $
Pred odprtjem:(0,74 %)−0,00010
0,013 $
Konec trgovanja: 18. okt., 20:00:00 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
0,0090 $
Letni razpon
0,0042 $ - 0,037 $
Tržna kapitalizacija
62,31 mio. USD
Povprečni obseg
153,16 tis.
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 5,94 mio. | 4,32 % |
Stroški poslovanja | 14,38 mio. | 0,52 % |
Čisti dohodek | −10,72 mio. | 50,83 % |
Čista dobičkovnost prihodkov | −180,46 | 52,87 % |
Earnings per share | — | — |
EBITDA | −9,51 mio. | 13,59 % |
Efektivna davčna stopnja | 0,79 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 63,89 mio. | −67,46 % |
Skupna sredstva | 233,31 mio. | −16,93 % |
Skupne obveznosti | 42,30 mio. | −30,22 % |
Celoten lastniški kapital | 191,00 mio. | — |
Shares outstanding | 12,22 mio. | — |
Razmerje P/B | 0,00 | — |
Donosnost sredstev | −11,12 % | — |
Donosnost kapitala | −13,33 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −10,72 mio. | 50,83 % |
Denar iz dejavnosti | — | — |
Denar iz naložb | — | — |
Denar iz financiranja | — | — |
Neto sprememba denarnih sredstev | — | — |
Prost denarni tok | — | — |
Vizitka
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Datum ustanovitve
2014
Spletno mesto
Zaposleni
322
